Michaël Hocquemiller is scientific director at Lysogene. He has 10 years of experience in research and drug development in the biotechnology industry, focused on neurodegenerative diseases. Dr. Hocquemiller has co-led the Phase 1 clinical trial in MPS IIIA, as well as designing drug candidates and pre-clinical work that have now advanced into clinical development. Before joining Lysogene, Dr. Hocquemiller worked as a research scientist at the Pasteur Institute focused on Sanfilippo syndrome neurophysiopathology and gene therapy correction in animal models. Dr. Hocquemiller has a PhD in neuroscience from the University Paris Descartes (Paris V) and a Masters in genetics from the University Pierre and Marie Curie (Paris VI).